Examining how shifting leadership patterns in breast cancer research signal growing international participation—and the ...
Cross-generational access: Digital technology adoption spans all age groups, with older adults becoming increasingly more comfortable using smartphones and tablets. Features like audio-visual consent, ...
In today’s ACT Brief, we revisit key insights from SCOPE Summit 2025 on AI and pragmatic trials, examine Genentech’s Phase III vamikibart data in uveitic macular edema, and highlight MJH Life Sciences ...
Revisit top insights from SCOPE Summit 2025, where industry leaders explored how artificial intelligence is reshaping trial ...
At ESMO 2025, AstraZeneca reported that Imfinzi plus BCG therapy reduced the risk of recurrence or death by 32% in patients ...
Unlock the advantage of pragmatic trials and improve efficiency and real-world relevance to reduce risk and strengthen ...
At AAO 2025, Genentech reported that vamikibart, a first-in-class IL-6–targeted antibody, led to rapid improvements in visual acuity and macular thickness in patients with uveitic macular edema, ...
Learn how early regulatory engagement, validated digital systems, and robust protocol design enable biotechs to run parallel ...
In contrast, a DL model can offer precise, AI-generated coding suggestions for adverse events and concomitant medications at up to 99% accuracy. The model can adapt to different scenarios, removing ...
Today’s ACT Brief highlights how artificial intelligence is transforming trial data management, why biotechs are embracing parallel execution to accelerate development, and new Phase III results ...
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical ...
At ESMO 2025, Eli Lilly’s Verzenio and Novartis’ Kisqali both demonstrated durable efficacy in hormone receptor-positive, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback